Strategies to reduce transfusion acquired vCJD

Area of Science:

• Transfusion Medicine
• Epidemiology
• Neurology

Background:

• Variant Creutzfeldt-Jakob disease (vCJD) is transmissible via blood transfusion.
• The risk of transfusion-transmitted vCJD is linked to the prevalence of infected donors.

Purpose of the Study:

• To estimate the potential number of transfusion-acquired vCJD cases in a less susceptible population.
• To evaluate strategies for preventing transfusion-acquired vCJD, including plasma importation and donor selection.

Main Methods:

• Epidemiological modeling based on current vCJD epidemic data.
• Risk assessment for transfusion-acquired vCJD.
• Cost-benefit analysis of plasma importation versus targeted donor selection.

Main Results:

• A maximum of 300 additional vCJD cases may occur in a less susceptible population.
• A maximum of one transfusion-acquired vCJD case is predicted within 3 years from plasma transfusion.
• Plasma importation is estimated to cost £30 million annually.

Conclusions:

• Targeting low-risk donors for blood component production (e.g., fresh frozen plasma, platelets) is a cost-effective alternative to plasma importation.
• This strategy can significantly reduce the incidence of transfusion-acquired vCJD without substantial additional healthcare costs.